Trial Profile
An Open-Label, Randomized, 2 Way Crossover, Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Corporation
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jan 2012 New trial record